Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 184

1.

Analysis of the phosphatidylinositol 3'-kinase signaling pathway in glioblastoma patients in vivo.

Choe G, Horvath S, Cloughesy TF, Crosby K, Seligson D, Palotie A, Inge L, Smith BL, Sawyers CL, Mischel PS.

Cancer Res. 2003 Jun 1;63(11):2742-6.

2.

Pharmacogenomic profiling of the PI3K/PTEN-AKT-mTOR pathway in common human tumors.

Xu G, Zhang W, Bertram P, Zheng XF, McLeod H.

Int J Oncol. 2004 Apr;24(4):893-900.

PMID:
15010827
4.

A phosphatidylinositol 3-kinase/Akt/mTOR pathway mediates and PTEN antagonizes tumor necrosis factor inhibition of insulin signaling through insulin receptor substrate-1.

Ozes ON, Akca H, Mayo LD, Gustin JA, Maehama T, Dixon JE, Donner DB.

Proc Natl Acad Sci U S A. 2001 Apr 10;98(8):4640-5.

7.

Activation of the anti-apoptotic Akt/protein kinase B pathway in human malignant gliomas in vivo.

Schlegel J, Piontek G, Mennel HD.

Anticancer Res. 2002 Sep-Oct;22(5):2837-40.

PMID:
12530006
8.

Inhibition of ILK in PTEN-mutant human glioblastomas inhibits PKB/Akt activation, induces apoptosis, and delays tumor growth.

Edwards LA, Thiessen B, Dragowska WH, Daynard T, Bally MB, Dedhar S.

Oncogene. 2005 May 19;24(22):3596-605.

PMID:
15782140
9.

mTOR promotes survival and astrocytic characteristics induced by Pten/AKT signaling in glioblastoma.

Hu X, Pandolfi PP, Li Y, Koutcher JA, Rosenblum M, Holland EC.

Neoplasia. 2005 Apr;7(4):356-68.

11.

PKB/Akt mediates radiosensitization by the signaling inhibitor LY294002 in human malignant gliomas.

Nakamura JL, Karlsson A, Arvold ND, Gottschalk AR, Pieper RO, Stokoe D, Haas-Kogan DA.

J Neurooncol. 2005 Feb;71(3):215-22.

PMID:
15735908
13.

Frequent PTEN genomic alterations and activated phosphatidylinositol 3-kinase pathway in basal-like breast cancer cells.

Marty B, Maire V, Gravier E, Rigaill G, Vincent-Salomon A, Kappler M, Lebigot I, Djelti F, Tourdès A, Gestraud P, Hupé P, Barillot E, Cruzalegui F, Tucker GC, Stern MH, Thiery JP, Hickman JA, Dubois T.

Breast Cancer Res. 2008;10(6):R101. doi: 10.1186/bcr2204.

15.

Reduced PTEN expression in breast cancer cells confers susceptibility to inhibitors of the PI3 kinase/Akt pathway.

DeGraffenried LA, Fulcher L, Friedrichs WE, Grünwald V, Ray RB, Hidalgo M.

Ann Oncol. 2004 Oct;15(10):1510-6.

PMID:
15367412
16.

Protein kinase B (PKB/Akt) activity is elevated in glioblastoma cells due to mutation of the tumor suppressor PTEN/MMAC.

Haas-Kogan D, Shalev N, Wong M, Mills G, Yount G, Stokoe D.

Curr Biol. 1998 Oct 22;8(21):1195-8.

17.
18.

Src family protein-tyrosine kinases alter the function of PTEN to regulate phosphatidylinositol 3-kinase/AKT cascades.

Lu Y, Yu Q, Liu JH, Zhang J, Wang H, Koul D, McMurray JS, Fang X, Yung WK, Siminovitch KA, Mills GB.

J Biol Chem. 2003 Oct 10;278(41):40057-66.

19.

Vascular endothelial growth factor activates PI3K/Akt/forkhead signaling in endothelial cells.

Abid MR, Guo S, Minami T, Spokes KC, Ueki K, Skurk C, Walsh K, Aird WC.

Arterioscler Thromb Vasc Biol. 2004 Feb;24(2):294-300.

Items per page

Supplemental Content

Support Center